116755-59-0

Basic information

• Product Name: 4-(2-bromoethoxy)phenylamine
• Synonyms: 4-(2-bromoethoxy)phenylamine
• CAS NO: 116755-59-0
• Molecular Weight: 216.077
• Mol File: 116755-59-0.mol

Chemical Properties

• CAS DataBase Reference: 4-(2-bromoethoxy)phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-bromoethoxy)phenylamine(116755-59-0)
• EPA Substance Registry System: 4-(2-bromoethoxy)phenylamine(116755-59-0)

Safety Data

• Hazardous Substances Data: 116755-59-0(Hazardous Substances Data)

Upstream product

• 13288-06-7 1-(2-bromoethoxy)-4-nitrobenzene 
• 123-30-8 4-amino-phenol 
• 106-93-4 ethylene dibromide 
• 100-02-7 4-nitro-phenol 
• 103-90-2 4-acetaminophenol 
• 57011-90-2 1-bromo-2-(4-acetamidophenoxy)ethane 

Downstream Products

• 75912-83-3 4-(2-imidazol-1-yl-ethoxy)-phenylamine 
• 915287-90-0 toluene-4-sulphonic acid (S)-2-[4-(3-{2-[3-(2-cyano-phenoxy)-2-hydroxy-propylamino]-ethyl}-ureido)-phenoxy]-ethyl ester 
• 915287-89-7 (S)-N-[4-(2-bromo-ethoxy)-phenyl]-N'-[2-[3-(2-cyanophenoxy)-2-hydroxy-propylamino]-ethyl]-urea 
• 915287-83-1 [2-[3-(4-(2-bromo-ethoxy)-phenyl)-ureido]-ethyl]-carbamic acid t-butyl ester 
• 915287-86-4 N-(2-amino-ethyl)-N'-[4-(2-bromo-ethoxy)-phenyl]-urea 
• 959514-05-7 (E)-4-(2-(4-(2-bromoethoxy)phenyl)diazenyl)phenol 
• 856370-77-9 4-(2-bromo-ethoxy)-N,N-bis-(2-hydroxy-ethyl)-aniline 
• 915287-81-9 4-(2-bromo-ethoxy)-phenylisocyanate 

Relevant articles and documents

Design and synthesis of Tr?ger's base ditopic receptors: host-guest interactions, a combined theoretical and experimental study

Two flexible Tr?ger's base ditopic receptors C4TB and C5TB incorporating monoaza crown ether were designed and synthesized for bisammonium ion complexation. A comprehensive study of host-guest interactions was established by 1H NMR spectroscopy

Design, synthesis, and biological study of 4-[(2-nitroimidazole-1h-alkyloxyl)aniline]-quinazolines as EGFR inhibitors exerting cytotoxicities both under normoxia and hypoxia

Purpose: In order to get novel EGFR inhibitors exerting more potency in tumor hypoxia than in normoxia. Methods: A series of 4-[(2-nitroimidazole-1H-alkyloxyl)aniline]-quinazolines were designed and synthesized, and their in vitro cytotoxicity and EGFR inhibitory activity were evaluated. Molecule docking study was performed for the representative compound. Results: The structure-activity relationship (SAR) studies revealed that compounds bearing both meta-chloride and para-(2-nitroimidazole-1H-alkyloxy) groups on the aniline displayed potent inhibitory activities both in enzymatic and cellular levels. The most promising compound 16i potently inhibited EGFR with an IC50 value of 0.12 μM. Meanwhile, it manifested more potent cytotoxicity than the positive control lapatinib under tumor normoxia and hypoxia conditions (IC50 values of 1.59 and 1.09 μM against A549 cells, 2.46 and 1.35 μM against HT-29 cells, respectively). The proposed binding model of 16i in complex with EGFR was displayed by the docking results. Conclusion: This study provides insights for developing hypoxia-activated kinase inhibitors.

Synthesis of an 18F-labelled high affinity β1- adrenoceptor PET radioligand based on ICI 89,406

To date, some non-selective β-adrenoceptor (β-AR) positron emission tomography (PET) radioligands are in clinical use, but no PET radioligand for the selective imaging of cardiac β1-ARs is clinically available. Therefore, the aim of this study

A multi-mode-driven molecular shuttle: Photochemically and thermally reactive azobenzene rotaxanes

The shuttling process of α-CyD in three rotaxanes (1-3) containing α-cyclodextrin (α-CyD) as a ring, azobenzene as a photoactive group, viologen as an energy barrier for slipping of the ring, and 2,4-dinitrobenzene as a stopper was investigated. The trans

1-[(Aryloxy)alkyl]-1H-imidazoles as inhibitors of neuronal nitric oxide synthase

A series of 1-[(aryloxy)alkyl]-1 H-imidazoles were synthesized from imidazole and various (aryloxy)alkyl bromides and tested for inhibitory activity against the three isoforms of nitric oxide synthase. 1-[2-(4-Bromophenoxy)ethyl]-1 H-imidazole and 1-[2-[4-(trifluoromethyl)phenoxy]ethyl]-1H-imidazole showed inhibitory activity against the neuronal isoform but were less potent against the endothelial isoform. Thus they could be considered interesting for their selectivity. The remaining compounds had only modest activity.